
(AGENPARL) – SILVER SPRING mar 30 maggio 2023 This listing includes?accelerated approvals?(AAs) for non-malignant hematological, neurological, and other disorder indications?with postmarketing trials that have been subsequently withdrawn, and are therefore, no longer FDA-approved.
Fonte/Source: http://www.fda.gov/drugs/accelerated-approval-program/withdrawn-non-malignant-hematological-neurological-and-other-disorder-indications-accelerated